The SUNMO trial demonstrated that the combination of mosunetuzumab and polatuzumab vedotin improved overall response rate and progression-free survival compared to R-GemOx in transplant-ineligible large B-cell lymphoma patients.
Study
|
Phase III, randomized, open-label study [SUNMO] |
| Transplant-ineligible patients with refractory/relapsed large B-cell lymphoma (LBCL) |
| Mosunetuzumab + Polatuzumab (n=138) vs R-GemOx (n=70)
|
Efficacy
|
ORR: 70% vs 40% (M+P vs. R-GemOx)(p $lt;0.0001) |
| CR: 51% vs 24% |
| mPFS: 11.5 mos vs 3.8 mos (HR 0.41 [0.3-0.6]) |
| mOS: 18.7 mos vs 13.6 mos (HR 0.80 [0.5-1.2].
|
Safety
|
Grade >=3 AE: Neutropenia (33% vs 31%), Thrombocytopenia (2.2% vs 36%), Anemia (5.9% vs 19%). |
| CRS: 26% in Mosun-Pola (0.7% Grade 3).
|
J Clin Oncol. Published online October 2, 2025
http://doi.org/10.1200/JCO-25-01957
Reviewed by Ulas D. Bayraktar, MD on Dec 8, 2025
